Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23538215 | 1.00 | SYK (0.56) | SYKCTSKFOLH1CTSLCTSS | |
| SCHEMBL5970914 | 1.00 | SYK (0.56) | SYKCTSKFOLH1CTSLCTSS | |
| SCHEMBL9819558 | 0.91 | SYK (0.55) | SYKCTSKCTSLCTSSCTSB | |
| SCHEMBL13570900 | 0.91 | SYK (0.55) | SYKCTSKCTSLCTSSCTSB | |
| SCHEMBL13570899 | 0.91 | SYK (0.55) | SYKCTSKCTSLCTSSCTSB | |
| SCHEMBL3425337 | 0.91 | SIRT2 (0.56) | SYKCTSKFOLH1CTSLCTSS | |
| SCHEMBL2578492 | 0.90 | SYK (0.54) | SYKCTSKCTSLCTSSCTSB | |
| SCHEMBL7215282 | 0.90 | SYK (0.54) | SYKCTSKCTSLCTSSCTSB | |
| SCHEMBL2578490 | 0.90 | SYK (0.54) | SYKCTSKCTSLCTSSCTSB | |
| SCHEMBL7290254 | 0.90 | CTSK (0.54) | SYKCTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2025-12-11 | — | — | US | disclosed |
| EP-4628499-A1 | POLYPEPTIDE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025130990-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG CONJUGATE AND ANTIBODY-DRUG CONJUGATE | 亚飞（上海）生物医药科技有限公司 | 2025-06-26 | — | — | WO | disclosed |
| CN-120202212-A | Polypeptide inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-115867548-B | RIP1K inhibitors | 里格尔药品股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119562958-A | Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof | 安进公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12178842-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4426727-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| US-5747499-A | CYCLOPENTAQUINAZOLINE COMPOUNDS CYCLOPENTAQUINAZOLINE COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
| EP-0761668-A2 | Non-classical antifolates | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-03-12 | — | — | EP | disclosed |
| EP-0758328-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INTERNATIONAL LIMITED (GB) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030673-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| EP-0341081-B1 | Novel amino acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-07-05 | — | — | EP | disclosed |
| US-5317021-A | Analgesics, anticonvulsants | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-05-31 | — | — | US | disclosed |
| US-5280034-A | Bis-heterocyclic prostaglandin analogs | E. R. SQUIBB & SONS, INC. (US) | 1994-01-18 | — | — | US | disclosed |
| US-5202340-A | Analgesics, anticonvulsants, anxiolytic agents, inhibitors for enkephalinases | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| US-5017589-A | Analgesic, antianxiety, anticonvulsant | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0341081-A2 | Novel amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375544-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | MAN2B1, GBA1, SSTR1 | SYK 1808/4885CTSK 565/4885FOLH1 337/4885 |
| US-12178842-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | SYK 2553/4885CTSK 193/4885FOLH1 1717/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | SYK 3437/4885CTSK 539/4885FOLH1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.